Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7053 · 1 trial · 1 indication
The safety and tolerability after multiple doses of AZD7503 in healthy Japanese participants will be evaluated.
| Arm | Type | Description |
|---|---|---|
| AZD7503 | EXPERIMENTAL | Participants will subcutaneously receive AZD7503. |
| Placebo | PLACEBO_COMPARATOR | Participants will subcutaneously receive placebo. |
| Name | Type | Description |
|---|---|---|
| AZD7053 | DRUG | Randomised participants will receive AZD7503 subcutaneously. |
| Placebo | DRUG | Randomised participants will receive placebo subcutaneously. |
Inclusion Criteria: * For Japanese participants: A Japanese participant is defined as having both parents and 4 Japanese grandparents as confirmed by the interview. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan. Participant...
AZD7053 is an investigational small molecule drug being developed by AstraZeneca PLC. It is in Phase 1 clinical development, and the specific disease or condition it is intended to treat has not been disclosed. It is not approved for any use.
AZD7053 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating this small molecule asset.
AZD7053 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Only early-stage human testing has been conducted so far.
AZD7053 has been studied in one Phase 1 trial, NCT06093542, titled a study to investigate the safety, tolerability, and pharmacokinetics of AZD7503 in Japanese healthy participants. The trial enrolled 12 healthy volunteers in Japan, was placebo controlled and randomized, and is now completed.
The molecular target of AZD7053 has not been disclosed. AstraZeneca has described AZD7053 only as a small molecule in Phase 1 development, without publicly identifying the biological target or pathway it acts on.
No. AZD7053 is an investigational drug in Phase 1 clinical development and is not FDA approved. Its only completed trial, NCT06093542, evaluated safety, tolerability, and pharmacokinetics in 12 healthy Japanese participants rather than testing the drug for a specific disease.